Arrowhead Pharmaceuticals, Inc. (BVMF:A2RR34)

Market Cap	45.17B +51.2%
Revenue (ttm)	3.47B +16.8%
Net Income	-1.66B
EPS	-1.57
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	40.96
Previous Close	40.96
Day's Range	40.96 - 40.96
52-Week Range	25.26 - 59.95
Beta	1.37
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 711
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A2RR34

Financial Performance

In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Nov 9, 2026

Data Sources Report a data error